Updated clinical guidelines on Effient treatment for ACS patients

19. November 2009 06:53

Effient® (prasugrel) tablets, a new antiplatelet medicine, was added as a treatment option in two clinical guideline updates: one for patients receiving percutaneous coronary intervention (PCI) and a second one for patients with ST elevation myocardial infarction (STEMI), or severe heart attack. [More]

6c3c37d1-a27e-4155-9d6e-23f76b32f7c3|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Angioplasty, Atherosclerosis, Blood Clot, Cardiology, Diabetes, Diabetes Mellitus, Effient, Hyperlipidemia, Ibuprofen, Neoplasm, Prasugrel, Stent, Stomach Ulcer, Stroke, Thrombosis, Transient Ischemic Attack, Ulcer, Warfarin

Findings of Merck's anacetrapib phase IIb study presented at the AHA sessions

18. November 2009 05:33

In a phase IIb study in 589 patients with primary hypercholesterolemia or mixed hyperlipidemia treated with anacetrapib as monotherapy or co-administered with atorvastatin, there were persistent lipid effects in the higher dose arms in both the monotherapy and co-administration treatment groups eight weeks after stopping active therapy with anacetrapib. [More]

79a2602b-2988-49f0-9b90-11aca5b51ba0|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Anacetrapib, Atherosclerosis, Atorvastatin, Blood Pressure, Cholesterol, Coronary Heart Disease, Hypercholesterolemia, Hyperlipidemia, Lipoprotein

Upsher-Smith Laboratories publishes results of SLIM Study

17. November 2009 04:10

Results of the SLIM Study ("Slo-Niacin® and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia") were recently published in the Journal of Clinical Lipidology. [More]

fb3789c9-4d82-442c-a5f1-72d2e21cad7b|0|.0

Posted in: Medical Condition News | Miscellaneous News

Tags: Anti-Inflammatory, Antioxidant, Atherosclerosis, Atorvastatin, Brain, Calcium, Cholesterol, Hyperlipidemia, Lipoprotein, Myopathy, Pfizer, Statin, Stroke, Triglyceride

Additional data from Aegerion Pharmaceuticals' ongoing lomitapide Phase III trial

16. November 2009 11:17

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of cardiovascular and metabolic disease, today announced additional data from its ongoing Phase III trial involving its lead cholesterol management compound, lomitapide (AEGR-733), which is a microsomal triglyceride transfer protein (MTP) inhibitor small molecule drug. [More]

6d99c465-4ac5-45c6-be10-593c6ec363a1|0|.0

Posted in: Medical Condition News | Disease/Infection News

Tags: Cholesterol, Dyslipidemia, Hypercholesterolemia, Hyperlipidemia, Life Expectancy, Lipoprotein, Triglyceride

MinuteClinic praises practitioners for providing affordable medical treatment and quality patient-centered care

12. November 2009 03:57

In celebration of National Nurse Practitioner Week (Nov. 8-14), MinuteClinic, the pioneer and largest provider of retail health care centers in the United States, salutes practitioners across the country who deliver patient-centered care and help to increase access to high-quality, affordable medical treatment. [More]

8c695bef-965b-49a1-b66d-5b982ec68499|0|.0

Posted in: Healthcare News

Tags: Diabetes, Education, Hyperlipidemia, Influenza, Nursing, Tetanus

MicroDose Therapeutx acquires potential compounds for treatment of respiratory syncytial virus

10. November 2009 01:46

MicroDose Therapeutx Inc. (formerly MicroDose Technologies) today announced that it has acquired a portfolio of compounds for the potential treatment of respiratory syncytial virus (RSV) from ViroPharma Incorporated (Exton, PA). The lead investigational compound in the portfolio is an inhalable small molecule fusion inhibitor, now called MDT-637. [More]

4bdde061-b350-42b8-9fb8-48070b8c5617|0|.0

Posted in: Disease/Infection News | Pharmaceutical News

Tags: Antibody, Asthma, Diabetes, Hyperlipidemia, Influenza, Prophylaxis, Respiratory Disease, Virus

Hospitalization and death of H1N1 patients can occur at all ages, says study

4. November 2009 04:08

In contrast with some common perceptions regarding 2009 influenza A(H1N1) infections, an examination of cases in California indicates that hospitalization and death can occur at all ages, and about 30 percent of hospitalized cases have been severe enough to require treatment in an intensive care unit, according to a study in the November 4 issue of JAMA. [More]

d1c18417-35a3-49f5-8577-81ed53a32d95|0|.0

Posted in: Disease/Infection News | Healthcare News

Tags: Cough, H1N1, Hyperlipidemia, Influenza, Intensive Care, Obesity, Pandemic, Pneumonia, Virus

Conference to address the need for gender specific diagnostic strategies for women

31. October 2009 03:21

The 'Red Alert for Women's Hearts' conference, taking place on 5 November 2009, at the European Heart House, Sophia Antipolis, France, will address the subject of Women and CVD. The conference is jointly organised by the European Society of Cardiology (ESC) and European Heart Network (EHN), as part of Work Package 6 of the EuroHeart project . [More]

bff1a86c-ba58-4c18-ada9-97e1250e358a|0|.0

Posted in: Medical Condition News | Women's Health News

Tags: Cancer, Cardiology, Cholesterol, Diabetes, Heart Failure, HIV/AIDS, Hyperlipidemia, Malaria, Menopause, Metabolic Syndrome, Obesity, Pathology, Stroke, Tuberculosis

Impax Laboratories initiates patent challenge for TRICOR

30. October 2009 11:18

Impax Laboratories, Inc. today confirms that it has initiated a challenge of the patents listed by Abbott Laboratories in connection with its TRICOR® (fenofibrate) tablets, 48 mg and 145 mg. [More]

edc7fcb8-a187-4344-b51c-d7bde51ccbd3|0|.0

Posted in: Medical Patent News | Pharmaceutical News

Tags: Diet, Drug Delivery, Fenofibrate, Hypercholesterolemia, Hyperlipidemia, Hypertriglyceridemia, New Drug Application

Upsher-Smith Laboratories publishes data on Slo-Niacin and Lipitor combination study

28. October 2009 05:03

Results of the SLIM Study ("Slo-Niacin® and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia") were recently published in the Journal of Clinical Lipidology. [More]

b313203a-1bad-4ff7-ad3c-b8497af9957b|1|5.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Anti-Inflammatory, Antioxidant, Atherosclerosis, Atorvastatin, Brain, Calcium, Cholesterol, Hyperlipidemia, Lipoprotein, Myopathy, Pfizer, Statin, Stroke, Triglyceride

Internet-based diet and exercise program shows promise in lowering healthcare costs

28. October 2009 01:37

Researchers from Boston University School of Medicine (BUSM) and Boston University School of Public Health (BUSPH) have shown that an employer-sponsored, internet-based diet and exercise program shows promise as a low-cost benefit to lower healthcare costs for those at higher risk for above-average costs and healthcare utilization such as cardiac, hyperlipidemia, hypertension or diabetes patients. [More]

ad0d5d79-e214-471f-b4cf-17fe8a6ff1e6|0|.0

Posted in: Disease/Infection News | Healthcare News

Tags: Blood Pressure, Cholesterol, Diabetes, Diet, Exercise, Health Insurance, Hyperlipidemia, Nutrition

Ligand Pharmaceuticals and Metabasis Therapeutics enter into definitive merger agreement

27. October 2009 08:30

Ligand Pharmaceuticals Incorporated and Metabasis Therapeutics, Inc. (NASDAQ: MBRX) announced today they have entered into a definitive merger agreement under which Ligand will acquire all of the outstanding shares of Metabasis. [More]

7c380c45-da9b-441e-88e7-a84aa00241f0|0|.0

Posted in: Business / Finance

Tags: Acadesine, Adenosine, Anemia, Arthritis, Asthma, Biotechnology, Burn, Cancer, Cell, Cholesterol, Diabetes, Gene Expression, Hepatitis B, Hepatitis C, Hepatocellular Carcinoma, Hyperlipidemia, Investment, Lipids, Liver Cancer, Obesity, Osteoporosis, Pfizer, Psoriasis, Rheumatoid Arthritis, Type 2 Diabetes

Ligand Pharmaceuticals, Metabasis Therapeutics enter into merger agreement

27. October 2009 08:28

Ligand Pharmaceuticals Incorporated and Metabasis Therapeutics, Inc. (NASDAQ: MBRX) announced today they have entered into a definitive merger agreement under which Ligand will acquire all of the outstanding shares of Metabasis. [More]

549fb6c9-8fbe-4019-8451-a4218251271f|0|.0

Posted in: Business / Finance

Tags: Acadesine, Adenosine, Anemia, Arthritis, Asthma, Biotechnology, Burn, Cancer, Cell, Cholesterol, Diabetes, Gene Expression, Hepatitis B, Hepatitis C, Hepatocellular Carcinoma, Hyperlipidemia, Investment, Lipids, Liver Cancer, Obesity, Osteoporosis, Pfizer, Psoriasis, Rheumatoid Arthritis, Type 2 Diabetes

LIVALO statin effective than simvastatin in reducing lipid levels

22. October 2009 08:44

New Phase III data published today in "Current Medical Research and Opinion" highlight that the recommended starting dose of 2 mg of LIVALO (pitavastatin), a novel synthetic statin, was statistically superior to simvastatin at a dose of 20 mg over 12 weeks in reducing low-density lipoprotein cholesterol [More]

2ff0cbc3-df08-424b-bd9a-97d453726416|1|2.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Atherosclerosis, Cholesterol, Coronary Heart Disease, Diabetes, Diet, Dyslipidemia, Education, Fenofibrate, Hospital, Hypercholesterolemia, Hyperlipidemia, Lipoprotein, Livalo, Metabolism, Pitavastatin, Statin, Stroke

Amarin selects Medpace as CRO for its Phase 3 AMR101 MARINE clinical study

19. October 2009 10:00

Amarin Corporation plc today announced that it has executed an agreement with Medpace, Inc. (‘Medpace’), a leading Contract Research Organization (CRO) with expertise in conducting clinical trials in cardiovascular and metabolic disease, to engage their services in the execution of its Phase 3 clinical trials with AMR101 in patients with very high triglyceride levels (the AMR101 MARINE Study) and mixed dyslipidemia. [More]

0af765e7-2554-46fa-9494-82d42a23bfd7|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Biotechnology, Cardiovascular Disease, Cholesterol, Dyslipidemia, Hyperlipidemia, Hypertriglyceridemia, Lipoprotein, Myasthenia Gravis, Nervous System, Statin, Triglyceride

Free!

Recent Comments

Twitter

Information

Hyperlipidemia News and Research

Updated clinical guidelines on Effient treatment for ACS patients

Findings of Merck's anacetrapib phase IIb study presented at the AHA sessions

Upsher-Smith Laboratories publishes results of SLIM Study

Additional data from Aegerion Pharmaceuticals' ongoing lomitapide Phase III trial

MinuteClinic praises practitioners for providing affordable medical treatment and quality patient-centered care

MicroDose Therapeutx acquires potential compounds for treatment of respiratory syncytial virus

Hospitalization and death of H1N1 patients can occur at all ages, says study

Conference to address the need for gender specific diagnostic strategies for women

Impax Laboratories initiates patent challenge for TRICOR

Upsher-Smith Laboratories publishes data on Slo-Niacin and Lipitor combination study

Internet-based diet and exercise program shows promise in lowering healthcare costs

Ligand Pharmaceuticals and Metabasis Therapeutics enter into definitive merger agreement

Ligand Pharmaceuticals, Metabasis Therapeutics enter into merger agreement

LIVALO statin effective than simvastatin in reducing lipid levels

Amarin selects Medpace as CRO for its Phase 3 AMR101 MARINE clinical study

Recent Articles

Free!

Recent Comments

Twitter

Information

Hyperlipidemia News and Research

Medical News Cloud

Recent Articles